These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 16249355)

  • 1. Helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b.
    Hurley KE; Chapman PB
    Oncologist; 2005 Oct; 10(9):739-42. PubMed ID: 16249355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b".
    Tarhini AA; Shipe-Spotloe J; DeMark M; Agarwala SS; Kirkwood JM
    Oncologist; 2006 May; 11(5):538-9; author reply 539-40. PubMed ID: 16720861
    [No Abstract]   [Full Text] [Related]  

  • 3. Systemic immune changes associated with adjuvant interferon-α2b-therapy in stage III melanoma patients: failure at the effector phase?
    Chevolet I; Schreuer M; Speeckaert R; Neyns B; Hoorens I; van Geel N; Krüse V; Hennart B; Allorge D; Van Gele M; Brochez L
    Melanoma Res; 2015 Aug; 25(4):357-61. PubMed ID: 26050145
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toxicity of combined treatment of adjuvant irradiation and interferon alpha2b in high-risk melanoma patients.
    Conill C; Jorcano S; Domingo-Domènech J; Marruecos J; Vilella R; Malvehy J; Puig S; Sánchez M; Gallego R; Castel T
    Melanoma Res; 2007 Oct; 17(5):304-9. PubMed ID: 17885585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent adjuvant radiotherapy and interferon-alpha2b for resected high risk stage III melanoma -- a retrospective single centre study.
    Gyorki DE; Ainslie J; Joon ML; Henderson MA; Millward M; McArthur GA
    Melanoma Res; 2004 Jun; 14(3):223-30. PubMed ID: 15179193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retinopathy associated with adjuvant high-dose interferon-α2b in a patient with resected melanoma: a case report and review of the literature.
    Monzon JG; Hammad N; Stevens SD; Dancey J
    Oncologist; 2012; 17(3):384-7. PubMed ID: 22334452
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
    Varker KA; Biber JE; Kefauver C; Jensen R; Lehman A; Young D; Wu H; Lesinski GB; Kendra K; Chen HX; Walker MJ; Carson WE
    Ann Surg Oncol; 2007 Aug; 14(8):2367-76. PubMed ID: 17534686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study.
    Gogas H; Bafaloukos D; Ioannovich J; Skarlos D; Polyzos A; Fountzilas G; Kalofonos HP; Aravantinos G; Tsoutsos D; Panagiotou P; Frangia K; Petrakopoulou T; Pectasides D;
    Anticancer Res; 2004; 24(3b):1947-52. PubMed ID: 15274382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recombinant α-2 interferon in preventing the progression of melanoma].
    Korovin SI; Kukushkina MN; Palivets AIu; Fil'chakov FV; Shumilina ES; Ostafĭchuk VV
    Lik Sprava; 2013 Dec; (8):21-30. PubMed ID: 25726673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma.
    Kirkwood JM; Resnick GD; Cole BF
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S16-23. PubMed ID: 9122729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose adjuvant interferon for stage III malignant melanoma.
    Inman JL; Russell GB; Savage P; Levine EA
    Am Surg; 2003 Feb; 69(2):127-30. PubMed ID: 12641352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant high-dose interferon alfa-2b in patients with high-risk melanoma.
    Jonasch E; Kumar UN; Linette GP; Hodi FS; Soiffer RJ; Ryan BF; Sober AJ; Mihm MC; Tsao H; Langley RG; Cosimi BA; Gadd MA; Tanabe KK; Souba W; Haynes HA; Barnhill R; Osteen R; Haluska FG
    Cancer J; 2000; 6(3):139-45. PubMed ID: 10882328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment patterns of adjuvant interferon-α2b for high-risk melanoma: a retrospective study of the Grupo Español Multidisciplinar de Melanoma - Prima study.
    Espinosa E; Soriano V; Malvehy J; Berrocal A; Martínez de Prado P; Quindós M; Soria A; Márquez-Rodas I; Palacio I; Cerezuela P; López-Vivanco G; Alonso L; Samaniego E; Ballesteros A; Puértolas T; Díaz-Beveridge R; de la Cruz-Merino L; López Castro R; López López R; Stevinson K; Del Barrio P; Tornamira MV; Guillém V; Martín-Algarra S
    Melanoma Res; 2016 Jun; 26(3):278-83. PubMed ID: 26958991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
    Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
    Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.
    Navid F; Furman WL; Fleming M; Rao BN; Kovach S; Billups CA; Cain AM; Amonette R; Jenkins JJ; Pappo AS
    Cancer; 2005 Feb; 103(4):780-7. PubMed ID: 15660397
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on the role of adjuvant interferon for high risk melanoma.
    Agarwala SS; Kirkwood JM
    Forum (Genova); 2000; 10(3):230-9. PubMed ID: 11007931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.
    Hancock BW; Wheatley K; Harris S; Ives N; Harrison G; Horsman JM; Middleton MR; Thatcher N; Lorigan PC; Marsden JR; Burrows L; Gore M
    J Clin Oncol; 2004 Jan; 22(1):53-61. PubMed ID: 14665609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Interferon for adjuvant therapy in melanoma; although approved, not indicated].
    Groenewegen G; Osanto S; van der Rhee HJ; Punt CJ
    Ned Tijdschr Geneeskd; 2000 Nov; 144(45):2160-2. PubMed ID: 11086492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b.
    Yurkovetsky ZR; Kirkwood JM; Edington HD; Marrangoni AM; Velikokhatnaya L; Winans MT; Gorelik E; Lokshin AE
    Clin Cancer Res; 2007 Apr; 13(8):2422-8. PubMed ID: 17438101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of pegylated interferon-alpha-2a in adjuvant therapy of intermediate and high-risk melanomas.
    Loquai C; Nashan D; Hensen P; Luger TA; Grabbe S; Sunderkötter C; Schiller M
    Eur J Dermatol; 2008; 18(1):29-35. PubMed ID: 18086586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.